Thank you to all who have joined us live for PrimaryCareNOW: A Pri-Med Virtual Conference. If you were not able to join us live, some sessions have been recorded and are available below.
Upcoming Virtual Conferences
Please join us next month for PrimaryCareNow on Wednesday−Friday, February 9−11.
Pri-Med has more virtual education planned. View our upcoming virtual conference schedule.
Agenda
CME/CE Accredited Session
Non-CME/CE Session
Sponsored by Industry
Click For Session Details
Session Times Listed in ET
8–11:30am ET CME/CE Accredited Session
Strategies for Effective Pain Management in Clinical Practice
Charles E. Argoff, MD, FABPM | Oscar A. de Leon-Casasola, MD | Katherine E. Galluzzi, DO, CMD, FACOFP
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management in Clinical Practice curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including nonopioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Charles E. Argoff, MD, FABPM
Professor of Neurology, Albany Medical College, Director, Comprehensive Pain Center, Albany Medical Center, Albany, NY
Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine, Senior Vice-Chair, The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Chief, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY
Katherine E. Galluzzi, DO, CMD, FACOFP
Professor and Chair, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
Supported by Opioid Analgesic REMS Program Companies
11:40am–12:25pm ET Non-CME Industry Theater
The Changing Treatment Landscape for Uncontrolled Asthma
Neil Skolnik, MD
This session will use a case presentation to discuss the impact of uncontrolled asthma and tools for assessing asthma control as well as asthma management. Learn to identify ways to customize management of uncontrolled asthma by exploring medication options for appropriate patients.
Neil Skolnik, MD
Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Sponsored by GlaxoSmithKline
12:35–1:35pm ET CME/CE Accredited Session
Managing Myths and Misconceptions about Chronic Idiopathic Constipation and Irritable Bowel Syndrome with Constipation
Philip Schoenfeld, MD, MSEd, MSc
This activity will provide an evidence-based approach to the diagnosis and management of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.
Philip Schoenfeld, MD, MSEd, MSc
Chief (Emeritus) - Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI
Supported by an educational grant from AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc..
1:45–2:45pm ET CME/CE Accredited Session
A Holistic Approach to Diabetes Care: Reducing HbA1c and Weight with Emerging Pharmacotherapies
Silvio E. Inzucchi, MD | Anne Peters, MD
This educational activity will review strategies to improve glycemic and extra-glycemic outcomes in patients with type 2 diabetes and explore the role of agents that target GIP and GLP-1 in the management of type 2 diabetes and obesity.
Silvio E. Inzucchi, MD
Professor of Medicine, Clinical Chief, Endocrinology, Medical Director, Yale Diabetes Center, Yale School of Medicine, Yale-New Haven Hospital
Anne Peters, MD
Professor of Clinical Medicine, USC Keck School of Medicine
Supported by an educational grant from Lilly.
2:55–3:40pm ET Non-CME Industry Theater
Path To Diagnosis, Mapping Symptoms of Inflammatory Back Pain
Chris Parker, DO
- Understand the causes and prevalence of chronic low back pain.
- Differentiate inflammatory back pain (IBP) from mechanical back pain.
- Learn the significance of IBP as a potential early symptom of ankylosing spondylitis (AS).
- Learn the importance of referring patients with IBP to a rheumatologist in a timely manner.
Chris Parker, DO
Sponsored by AbbVie Inc.
3:50–4:50pm ET CME/CE Accredited Session
COVID-19 Update: Panel Discussion (January 2022)
Ty J. Gluckman, MD, FACC, FAHA | Charles Vega, MD, FAAFP
In this COVID-19 update, faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.
Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine Director, UC Irvine Program in Medical Education for the Latino Community, Irvine, CA
5–5:45pm ET Non-CME Industry Theater
Shifting Perspectives: How Do You Choose the Next Oral Therapy for T2D?
Eden M. Miller, DO
Review the pathophysiology of T2D and the recommendations from relevant associations on the oral treatment options that should be used after metformin in the T2D treatment plan. Discuss head-to-head data for a once-daily treatment option from pivotal glycemic control trials and safety data from a cardiovascular outcomes trial, followed by dosing and administration information.
Eden M. Miller, DO
Diabetes Care, Obesity, Family Medicine, Founder, Diabetes and Obesity Care, LLC, Bend, Oregon
Sponsored by Novo Nordisk